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Contrary to other species in the Mycobacterium che-
lonae-abscessus complex, we reidentiﬁ  ed M. bolletii strains 
isolated from 4 respiratory patients and found these strains 
to be uniformly resistant to clarithromycin. No mutations 
previously associated with macrolide resistance in bacteria 
were detected in either the 23S rDNA or the genes encoding 
riboproteins L4 and L22.  
M
ycobacterium chelonae-abscessus complex (MCAC) 
members are opportunistic pathogens in patients 
with underlying pulmonary disorders (1–3). We recently de-
scribed M. bolletii as a new MCAC member (4); the patho-
gen was later isolated from 9% of cystic ﬁ  brosis patients (5). 
The initial description of M. bolletii suggested that it was 
highly resistant to antimicrobial drugs, including clarithro-
mycin (4). To gain a better appreciation of this resistance, 
we reidentiﬁ  ed MCAC isolates collected in our microbiolo-
gy laboratory, Timone Hospital, Marseilles, during the past 
10 years and performed in vitro susceptibility testing and 
sequencing of the 23S rDNA, L4, and L22 genes. 
Case Reports
Patient 1, a 47-year-old woman with an unremarkable 
medical history, sought treatment after a 3-week history of 
hemoptysis; radiographs showed bilateral micronodular in-
ﬁ  ltrates in the upper lung lobes. Blood tests showed a poly-
morphonuclear cell count of 9 × 103/mL and biological in-
ﬂ  ammatory syndrome. Bleeding in the left lobar bronchus 
was observed during bronchoscopy. Microbiologic results 
of a bronchial lavage specimen were negative, and micro-
scopic examination found no acid-fast bacilli. An isolate 
from a subsequent sputum sample was identiﬁ  ed later as M. 
bolletii, however. The patient was discharged. No further 
information is available for this patient.
Patient 2, a 76-year-old man who had received treat-
ment for pulmonary tuberculosis (TB) in 1976, sought 
treatment in November 1995 for hemoptysis and signs 
and symptoms of broncho-pulmonary infection. A chest 
radiograph showed a large cavity in the right upper lobe 
and inﬁ  ltrate in the left upper lobe. Two stomach aspirates 
yielded an isolate identiﬁ  ed as M. abscessus despite nega-
tive results of a direct microscopic examination; reﬁ  ned 
identiﬁ  cation performed 8 years later in 2003 found both 
isolates to be M. bolletii. The patient received rifampin, 
clarithromycin, isoniazid, and ciproﬂ  oxacin for 16 months. 
After an initial improvement, the patient continued to have 
an episodic cough and hemoptysis, and M. bolletii was 
grown from 2 sputum specimens; direct microscopic ex-
amination yielded acid-fast bacilli. In November 1998, the 
patient still had symptoms. In 2003, he was admitted to an 
intensive care unit for acute respiratory distress syndrome. 
A broncho-alveolar lavage specimen yielded a mixed cul-
ture of multidrug-resistant M. bolletii and Klebsiella pneu-
moniae despite negative results of direct examination. The 
patient eventually died of K. pneumoniae septicemia within 
days of his admission to the ICU.
Patient 3, a 77-year-old man who smoked 3 packs of 
cigarettes per month and who had a history of pulmonary 
TB, was admitted to Timone Hospital, Marseilles, in Octo-
ber 2000 with a diagnosis of bronchitis. Corticoid therapy 
was prescribed. In March 2001, the patient was admitted 
for respiratory insufﬁ  ciency. A chest radiograph showed 
diffuse bullous emphysema in both lungs. Microscopic ex-
amination of 1 sputum specimen and 1 bronchial aspirate 
yielded the presence of acid-fast bacilli that were later iden-
tiﬁ  ed as M. bolletii. The patient left the hospital without 
treatment, and no further information on his condition is 
available.
Patient 4, a 90-year-old woman, sought treatment with 
a temperature of 38°C, hemoptysis, and bilateral micronod-
ular inﬁ  ltrates of the upper lung lobes. She had a history 
of childhood pulmonary TB. Sputum specimens yielded 
mycobacteria that were identiﬁ  ed later as M. bolletii de-
spite negative results of direct examination. The patient 
remained febrile after 1 month of treatment with intrave-
nous imipenem and amikacin, her pulmonary condition 
worsened, and a sputum smear showed numerous acid-fast 
bacilli. The treatment regimen was changed to a combina-
tion of ciproﬂ  oxacin, clarithromycin, and ethambutol, but 
the patient died 2 weeks after treatment began.
The Study
Thirty-one isolates, previously identiﬁ  ed  as  M. ab-
scessus (n = 20) and M. chelonae (n = 11) by 16S rDNA 
sequencing from January 1996 through June 2007, were 
reidentiﬁ  ed by partial rpoB gene sequencing as described 
(6). The MICs of 22 antimicrobial drugs were determined 
by E-test (AB Biodisk, Solna, Sweden) after the culture 
was incubated for 3 days at 30°C. Data were interpreted 
by using the broth microdilution criteria (7). A 1,500-
bp fragment of the 23S rDNA (8), a 635-bp fragment of 
the L4 ribosomal protein (forward primer L4Absc7F: 5′-
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ATCGCAGTCAAGGCTCCGG-3′, reverse primer L4Ab-
sc642R: 5′-TCAGGCCGACACCTCCTC-3′), and a 471-
bp fragment of the L22 ribosomal protein (forward primer 
L22Absc1F: 5′-ATGACCACTACTACCGAAT-3′, reverse 
primer L22Absc471R: 5′-CTAGCTGGTGCCTCCCTT-3′) 
were PCR ampliﬁ  ed and sequenced from clarithromycin-
resistant isolates. The study was approved by local Ethics 
Committee, Marseilles Medical School.
Twelve of 31 isolates were identiﬁ  ed by rpoB sequenc-
ing as M. abscessus, 11 as M. chelonae, 4 as M. massil-
iense, and 4 as M. bolletii. M. abscessus and M. bolletii 
isolates showed no intraspeciﬁ  c rpoB sequence variation. 
In contrast, 0.7% sequence divergence was observed in M. 
chelonae (6 sequevars) and M. massiliense (3 sequevars) 
isolates (Figure). The 4 M. bolletii isolates were unique 
among these 31 MCAC isolates in that they were multi-
drug resistant (Table). The isolates exhibited clarithromy-
cin MICs >256 μg/mL, whereas the other MCAC isolates 
had clarithromycin MICs <2 μg/mL. The E-test is not a val-
idated method for MIC determination in rapidly growing 
mycobacteria, yet the results we obtained were similar to 
those previously reported for the reference broth microdi-
lution method (9). In the M. bolletii isolates, we found no 
substitutions, deletions, or insertions in domain V (A2058, 
A2059, C2611 position, Escherichia coli numbering) of the 
23S rDNA or in the L4 and L22 ribosomal protein genes.
Conclusions
M. bolletii is an emerging pathogen responsible for re-
spiratory tract infections in patients with underlying com-
promised respiratory function. In our study, M. bolletii was 
responsible for pulmonary infection in 3 of 4 patients (pa-
tients 2–4) (10). M. bolletii was repeatedly isolated from 
different samples from those 3 patients over a period of 
several weeks. A coexisting broncho-pulmonary disease 
was found in 3 of the 4 patients, and clinical features and 
radiograph patterns that suggested nontuberculous myco-
bacteria infection were observed in all 4 patients (10). In-
fected patients were >75 years of age. Three of 4 patients 
had hemoptysis and lung inﬁ  ltrates, M. bolletii was the 
sole organism isolated from respiratory tract specimens. 
In this study, 16S rDNA sequencing misidentiﬁ  ed 25% of 
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Table. Antimicrobial drug susceptibility test results (MICs) for Mycobacterium bolletii isolates* 
Antimicrobial agent  Patient 1  Patient 2  Patient 3  Patient 4 
Penicillin >32 >32 >32 >32
Amoxicillin >256 >256 >256 >256
Amoxicillin clavulanate (disc 20 μg + 10 μg) >4 >4 >4 >4
Cefoxitin >256 >256 >256 >256
Ceftriaxone >256 >256 >256 >256
Cefotaxime >256 >256 >256 >256
Imipenen >32 >32 >32 >32
Doxycycline >32 >32 >32 >32
Minocycline >256 >256 >256 >256
Clarithromycin >256 >256 >256 >256
Erythromycin >256 >256 >256 >256
Azithromycin >256 >256 >256 >256
Amikacin 32 48 32 48
Tobramycin >32 >32 >32 >32
Ciprofloxacin >32 >32 >32 >32
Ofloxacin >32 >32 >32 >32
Sparfloxacin >32 >32 >32 >32
Rifampicin >32 >32 >32 >32
Metronidazole >256 >256 >256 >256
Teicoplanine >256 >256 >256 >256
Vancomycin >256 >256 >256 >256
Trimethoprim-sulfamethoxazole >32 >32 >32 >32
*Values given in Pg/mL.
M. immunogenum sqvI (EU109285) 
M. chelonae sqvI (EU109286) (n = 1) 
M. chelonae sqvII (EU109287) (n = 1)
M. chelonae sqvIII (EU109288) (n = 4) 
M. chelonae sqvIII (EU109288) (n = 4) 
M. chelonae sqvV (EU109290) (n = 1)  
M. chelonae sqvVI (EU109291) (n = 1) 
M. bolletii sqvI (EU109293) (n = 4) 
M. massiliense sqvIII (EU109296) (n = 1)
M. massiliense sqvII (EU109295) (n = 1) 












M. mucogenicum group 
 M. abscessus sqvI (EU109292) (n = 12) 
Figure. Phylogenetic tree of different sequevars of Mycobacterium 
abscessus-chelonnae group isolates determined by rpoB-723 bp 
sequencing. Isolate identiﬁ  ed as M. bolletii is in boldface. Scale 
bar represents 1% sequence divergence. 31 MCAC isolates that were eventually identiﬁ  ed as M. 
massiliense and M. bolletii. This statistic agrees with ob-
servations made during the recent description of M. bolletii 
infection after mesotherapy (11).
Clarithromycin was administrated to 2 of the 4 pa-
tients, both of whom died within several weeks after treat-
ment began. The 4 M. bolletii isolates were highly resistant 
to clarithromycin, yet they did not harbor the 23S rDNA 
mutations that have been previously found in clarithromy-
cin-resistant  M. abscessus strains (12). Additionally, no 
mutations in riboproteins L4 and L22, which are associ-
ated with macrolide resistance in Streptococcus pneumo-
niae (13), were detected. RNA methylase genes erm[38], 
erm[39], and erm[40], which confer inducible macrolide 
resistance in M. fortuitum, M. smegmatis, M. mageritense, 
and M. wolinskyi, are absent in the MCAC (14). Further in-
vestigations are therefore needed to clarify the mechanism 
of clarithromycin resistance in M. bolletii.
Clarithromycin has been recommended as the ﬁ  rst-
line antimicrobial drug for treating rapidly growing myco-
bacteria infections in patients with compromised respira-
tory function (1,10). Patient deaths (3) have been linked 
to clarithromycin resistance, with a risk of secondary 
clarithromycin resistance during monotherapy estimated 
to be <10% (12). Recent studies showed that 21%–36% 
of MCAC isolates were resistant to clarithromycin (15). 
The recommendation for treating M. abscessus infec-
tion with clarithromycin was made before discovering M. 
bolletii, a multidrug-resistant species that mimics M. ab-
scessus. Our report illustrates that accurate species iden-
tiﬁ  cation and in vitro clarithromycin susceptibility testing 
should be recommended for MCAC isolates of clinical in-
terest. GenBank accession nos. were as follows: for 23S 
rDNA sequences, M. bolletii CIP 108541T (EU109306), 
M. massiliense CIP 108297T (EU109307), M. abscessus 
CIP 104536T (EU109308), and M. chelonae CIP 104535T 
(EU109309); for L4 sequences, M. bolletii CIP 108541T M. 
massiliense (EU779956), CIP 108297T (EU779957), M. 
abscessus CIP 104536T (EU779957), and M. chelonae CIP 
104535T (EU779958); and for L22 sequences M. bolletii 
CIP 108541T (EU779952), M. massiliense CIP 108297T 
(EU779953), M. abscessus CIP 104536T (EU779954), and 
M. chelonae CIP 104535T (could not be ampliﬁ  ed with the 
designed primers).   
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